XTEP INT'L (01368) plans to issue convertible bonds.
special step international (01368) announced that, in accordance with clause 8E (purchase) of the terms and conditions of the 2025 convertible bonds, the company or any of its subsidiaries may at any time and from time to time, within the limits of applicable laws and regulations, purchase the 2025 convertible bonds on the open market or through other means at any price. The company suggests repurchasing the 2025 convertible bonds in accordance with the above terms and conditions.
XTEP INT'L (01368) announces that, in accordance with the terms and conditions of the 2025 convertible bonds clause 8E (purchase), the company or any of its subsidiaries may, subject to applicable laws and regulations, buy back the 2025 convertible bonds at any time and at any price on the open market or through other means. The company recommends repurchasing the 2025 convertible bonds based on the above terms and conditions.
On January 30, 2026, the company signed a transaction agent agreement with a transaction agent, appointing the transaction agent to handle the proposed simultaneous repurchase transactions, including assisting the company in collecting letters of intent from 2025 convertible bond holders who may be willing to sell their holdings.
The company plans to issue convertible bonds to institutional investors. The company has appointed an agent to coordinate the pricing of the proposed bond issue. Once the bond terms (including issuance size, issuance price, and other terms) are finalized, the agent will enter into a subscription agreement with the company for the proposed bond issue.
The Board of Directors believes that through conducting simultaneous repurchase transactions and issuing bonds, the company will be able to extend the maturity structure of its debt. In addition, the proposed bond issue will bring the following additional benefits: provide additional funds to the company at a lower financing cost to fund the simultaneous repurchase transactions, with the remaining amount used for general corporate purposes; not have an immediate dilutive effect on the holdings of existing shareholders; and strengthen the company's capital base, and promote long-term development when the bonds are converted into new shares.
Related Articles

New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?
New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


